Literature DB >> 19217290

Mammalian animal models for Duchenne muscular dystrophy.

Raffaella Willmann1, Stefanie Possekel, Judith Dubach-Powell, Thomas Meier, Markus A Ruegg.   

Abstract

Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease that affects boys and leads to early death. In the quest for new treatments that improve the quality of life and in the search for a possible definitive cure, the use of animal models plays undoubtedly an important role. Therefore, a number of different mammalian models for DMD have been described. Much knowledge on the molecular mechanisms underlying the disease has arisen from studies in these animals. However, the use of different models does not often allow a direct comparison of results obtained in preclinical trials and therefore hinders a straightforward translational research. In the frame of "TREAT-NMD", a European Network of Excellence addressing the fragmentation in the assessment and treatment of neuromuscular diseases, we compare here the currently used mammalian animal models for DMD with the aim of selecting and recommending the most appropriate ones for preclinical efficacy testing of new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19217290     DOI: 10.1016/j.nmd.2008.11.015

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  88 in total

1.  Structural and functional evaluation of branched myofibers lacking intermediate filaments.

Authors:  Mariah H Goodall; Christopher W Ward; Stephen J P Pratt; Robert J Bloch; Richard M Lovering
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-16       Impact factor: 4.249

2.  Collaborating to bring new therapies to the patient--the TREAT-NMD model.

Authors:  K Bushby; S Lynn; T Straub
Journal:  Acta Myol       Date:  2009-07

3.  Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zürich, June 30th-July 1st 2008.

Authors:  Kanneboyina Nagaraju; Raffaella Willmann
Journal:  Neuromuscul Disord       Date:  2009-06-26       Impact factor: 4.296

4.  Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice.

Authors:  Raffaella Willmann; Annamaria De Luca; Michael Benatar; Miranda Grounds; Judith Dubach; Jean-Marc Raymackers; Kanneboyina Nagaraju
Journal:  Neuromuscul Disord       Date:  2011-07-06       Impact factor: 4.296

5.  rAAVrh74.MCK.GALGT2 Protects against Loss of Hemodynamic Function in the Aging mdx Mouse Heart.

Authors:  Rui Xu; Ying Jia; Deborah A Zygmunt; Paul T Martin
Journal:  Mol Ther       Date:  2019-01-15       Impact factor: 11.454

Review 6.  What do mouse models of muscular dystrophy tell us about the DAPC and its components?

Authors:  Charlotte Whitmore; Jennifer Morgan
Journal:  Int J Exp Pathol       Date:  2014-09-30       Impact factor: 1.925

7.  Architecture of healthy and dystrophic muscles detected by optical coherence tomography.

Authors:  Richard M Lovering; Sameer B Shah; Stephen J P Pratt; Wei Gong; Yu Chen
Journal:  Muscle Nerve       Date:  2013-02-04       Impact factor: 3.217

Review 8.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

Review 9.  Anchoring skeletal muscle development and disease: the role of ankyrin repeat domain containing proteins in muscle physiology.

Authors:  Jin-Ming Tee; Maikel P Peppelenbosch
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-08       Impact factor: 8.250

Review 10.  The roles of the dystrophin-associated glycoprotein complex at the synapse.

Authors:  Gonneke S K Pilgram; Saranyapin Potikanond; Richard A Baines; Lee G Fradkin; Jasprina N Noordermeer
Journal:  Mol Neurobiol       Date:  2009-11-09       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.